European Society for Medical Oncology

SHERPA: Unknown

People

  1. Motzer
    Motzer
  2. Abou-Alfa
    Abou-Alfa
  3. D'Angelo
    D'Angelo
  4. Drilon
    Drilon
  5. Jhaveri
    Jhaveri
  6. O'Reilly
    O'Reilly
  7. Rosenbaum
    Rosenbaum
  8. Rosenberg
    Rosenberg
  9. Tap
    Tap
  10. Yaeger
    Yaeger

Groups

  1. Department of Medicine (59)
  2. Solid Tumor Oncology Division (55)
  3. Gastrointestinal Oncology Service (16)
  4. Genitourinary Oncology Service (14)
  5. Hematologic Malignancies, Division of (8)
  6. Breast Medicine Service (7)
  7. Hematology-Oncology Fellows (7)
  8. Sarcoma Service (7)
  9. Thoracic Oncology (7)
  10. Weinberg Fellows (5)
Search Within
Formats
  1. Journal Article (57)
  2. Review (8)
  3. Editorial (2)
  4. Miscellaneous (2)
  5. Correspondence (1)
Groups
  1. Department of Medicine (59)
  2. Solid Tumor Oncology Division (55)
  3. Gastrointestinal Oncology Service (16)
  4. Genitourinary Oncology Service (14)
  5. Hematologic Malignancies, Division of (8)
  6. Breast Medicine Service (7)

More Groups

People
  1. Robert Motzer (8)
  2. Ghassan Abou-Alfa (5)
  3. Alexander Drilon (3)
  4. Eileen O'Reilly (3)
  5. Evan Rosenbaum (3)
  6. Jonathan Rosenberg (3)

More People

Years
  1. 2025 (16)
  2. 2024 (16)
  3. 2023 (9)
  4. 2022 (10)
  5. 2021 (7)
  6. 2020 (7)

More Years

Publications
  1. ESMO Open (70)

Results (70)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Translocation in bone and soft tissue sarcomas: A comprehensive epidemiological investigation
    Journal Article

    Kawaguchi, K.; Endo, M.; Shimada, E.; Kohashi, K.; Hirose, T.; Nabeshima, A.; Fujiwara, T.; Kawai, A.; Oda, Y.; Nakashima, Y.
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States
    Journal Article

    Tolaney, S. M.; Punie, K.; Carey, L. A.; Kurian, A. W.; Ntalla, I.; Sjekloca, N.; Shah, A.; Rehnquist, M. K.; Stokes, M.; Fraeman, K.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: Characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
    Journal Article

    Rugo, H. S.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Jhaveri, K. L.; Krivorotko, P.; Loibl, S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: Using clinical judgement over treatment criteria
    Journal Article

    Apolo, A. B.; Bellmunt, J.; Cordes, L.; Gupta, S.; Powles, T.; Rosenberg, J. E.; Van Der Heijden, M. S.
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: Retrospective study from the Ultra-Rare Sarcoma Working Group
    Journal Article

    Giani, C.; Denu, R. A.; Ljevar, S.; Gronchi, A.; Napolitano, A.; Rosenbaum, E.; Salawu, A.; Bajpai, J.; Connolly, E. A.; Lee, A. T. J.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: An international Delphi consensus report
    Review

    Schöffski, P.; Jones, R. L.; Agulnik, M.; Blay, J. Y.; Chalmers, A.; Italiano, A.; Pink, D.; Stacchiotti, S.; Valverde, C.; Vincenzi, B.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • An open-label study of pemigatinib in cholangiocarcinoma: Final results from FIGHT-202
    Journal Article

    Vogel, A.; Sahai, V.; Hollebecque, A.; Vaccaro, G. M.; Melisi, D.; Al Rajabi, R. M.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study
    Journal Article

    D'Angelo, S. P.; Lebbé, C.; Mortier, L.; Brohl, A. S.; Fazio, N.; Grob, J. J.; Prinzi, N.; Hanna, G. J.; Hassel, J. C.; Kiecker, F.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
    Review

    Curigliano, G.; Dent, R.; Earle, H.; Modi, S.; Tarantino, P.; Viale, G.; Tolaney, S. M.
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended follow-up from the phase III randomised CheckMate 9ER trial
    Journal Article

    Powles, T.; Burotto, M.; Escudier, B.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Porta, C.; Barrios, C. H.; Richardet, M.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save

    • European Society for Medical Oncology – authorized name for: